Sun Pharmaceutical Industries, Inc., on December 6, announced that it has entered into a licensing agreement with Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company specialising in the development of innovative drugs for immuno-inflammatory diseases. Under the terms of the agreement, Aclaris has exclusively granted Sun Pharma the rights to specific patents.
Open FlipConsidering the bullish bias with continuation in higher highs, higher lows formation for six days in a row and support-based buying for yet another session, experts expect the Nifty50 to touch 21,000 mark for the first time in the coming days, with support at the 20,700 levels, but on the other side, also advised to keep an eye on momentum indicator RSI (relative strength index).
Open FlipOn December 5, 19 Nifty stocks achieved either record highs or scaled their 52-week peaks. The Sensex saw a rise of 431 points, reaching 69,296, and the Nifty gained 168 points, closing at 20,855. The Nifty Bank registered an increase of 581 points, reaching 47,012, and the Nifty Midcap index experienced a gain of 204 points, closing at 44,123. The Nifty is maintaining a robust bullish momentum.
Open Flip